Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia 19Leukemia, Myeloid, Chronic-Phase 16Breast Neoplasms 11Neoplasm Metastasis 10Leukemia, Myeloid, Acute 8Blast Crisis 8Prostatic Neoplasms 7Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Recurrence 5Pancreatic Neoplasms 5Leukemia, Myeloid, Accelerated Phase 5Leukemia, Lymphocytic, Chronic, B-Cell 5Melanoma 4Gliosarcoma 4Glioblastoma 4Rectal Neoplasms 3Philadelphia Chromosome 3Lung Neoplasms 3Glioma 3Gastrointestinal Stromal Tumors 3Colorectal Neoplasms 3Colonic Neoplasms 3Brain Neoplasms 3Sarcoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2

Interventions

pembrolizumab 1nintedanib 1dactolisib 1avelumab 1Vorinostat 1Sunitinib 1Oxaliplatin 1Levoleucovorin 1Leucovorin 1Hydroxychloroquine 1Folfox protocol 1Fluorouracil 1Dasatinib 1DOXO-EMCH 1Cetuximab 1Bevacizumab 1BN 80927 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Malignant Solid Tumour × Dasatinib × Clear all
NCT00388427 2015-05-28

Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies

University of Pittsburgh

Phase 1 Completed
31 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡